Brexit: The View For Pharma In 2021 And Beyond

With the end of the Brexit transition period fast approaching, life sciences companies need to be ready for some major changes to drug regulations as well as the impact of new border and customs controls on the flow of medicines between Great Britain, Northern Ireland and the EU. In Vivo looks at what is at stake, and what still needs to be done, as the UK prepares to leave the EU single market and customs union at the beginning of 2021.

EU_UK

Whatever the outcome of the protracted and often painful negotiations on the future UK-EU trade and security relationship, the life sciences companies in the UK will be entering a very different regulatory landscape in January.

On the positive side, the UK will have its own, fully standalone medicines and medical devices regulator in the form...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.